| P2093 | author name string | Hui Li | |
| | Wenlong Tan | |
| | Xiang Gao | |
| | Qunfang Xu | |
| | Wenyan Fu | |
| | Hua Wu | |
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| | Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 |
| | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 |
| | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 |
| | Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study | Q27851763 |
| | The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 |
| | PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 |
| | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 |
| | Trastuzumab--mechanism of action and use in clinical practice | Q29615810 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 |
| | The PIK3CA gene as a mutated target for cancer therapy | Q33699378 |
| | A novel interaction between HER2/neu and cyclin E in breast cancer | Q33976264 |
| | Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 |
| | Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. | Q34354224 |
| | Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts | Q34694605 |
| | Overview of chemotherapy-induced diarrhea | Q35619374 |
| | HER2 therapy: molecular mechanisms of trastuzumab resistance. | Q35633712 |
| | Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer | Q36472437 |
| | Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function | Q36585794 |
| | Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer. | Q37307587 |
| | Recommendations for reporting outcome results in abdominal wall repair: results of a Consensus meeting in Palermo, Italy, 28-30 June 2012. | Q38106818 |
| | Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity | Q39908130 |
| | Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy | Q40138970 |
| | Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. | Q40169783 |
| | Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells | Q40321992 |
| | Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways | Q44127144 |
| | Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 |
| | Pooled analysis of diarrhea events in patients with cancer treated with lapatinib | Q46801526 |
| | Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 |
| | Trastuzumab--mechanism of action and use | Q81454475 |
| P433 | issue | 5 | |
| P921 | main subject | diarrhea | Q40878 |
| | meta-analysis | Q815382 |
| P304 | page(s) | 4077-4085 | |
| P577 | publication date | 2013-12-29 | |
| P1433 | published in | Tumor Biology | Q15757842 |
| P1476 | title | Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis | |
| P478 | volume | 35 | |